Charles Schwab’s Blueprint Medicines BPMC Stock Holding History

Charles Schwab’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-561,159	Closed	-$71.9M	–	3471
2025 Q2	$71.9M	Sell	561,159 -38,562	-6%	-$4.01M	0.01%	862
2025 Q1	$53.1M	Sell	599,721 -4,676	-0.8%	-$456K	0.01%	1030
2024 Q4	$52.7M	Buy	604,397 +7,165	+1%	+$656K	0.01%	1096
2024 Q3	$55.2M	Buy	597,232 +50,736	+9%	+$5.04M	0.01%	1059
2024 Q2	$58.9M	Buy	546,496 +45,361	+9%	+$4.54M	0.01%	944
2024 Q1	$47.5M	Buy	501,135 +25,072	+5%	+$2.15M	0.01%	1079
2023 Q4	$43.9M	Buy	476,063 +7,646	+2%	+$495K	0.01%	1073
2023 Q3	$23.5M	Sell	468,417 -14,066	-3%	-$752K	0.01%	1400
2023 Q2	$30.5M	Buy	482,483 +9,593	+2%	+$522K	0.01%	1201
2023 Q1	$21.3M	Buy	472,890 +4,431	+0.9%	+$200K	0.01%	1428
2022 Q4	$20.5M	Buy	468,459 +10,750	+2%	+$516K	0.01%	1422
2022 Q3	$30.2M	Buy	457,709 +12,491	+3%	+$802K	0.01%	1097
2022 Q2	$22.5M	Sell	445,218 -2,631	-0.6%	-$154K	0.01%	1315
2022 Q1	$28.6M	Buy	447,849 +9,854	+2%	+$707K	0.01%	1261
2021 Q4	$46.9M	Sell	437,995 -27,614	-6%	-$2.89M	0.01%	938
2021 Q3	$47.9M	Buy	465,609 +3,616	+0.8%	+$337K	0.02%	903
2021 Q2	$40.6M	Buy	461,993 +14,238	+3%	+$1.3M	0.01%	1019
2021 Q1	$43.5M	Buy	447,755 +35,381	+9%	+$3.53M	0.02%	940
2020 Q4	$46.2M	Buy	412,374 +18,782	+5%	+$1.98M	0.02%	810
2020 Q3	$36.5M	Buy	393,592 +590	+0.2%	+$45.4K	0.02%	835
2020 Q2	$30.7M	Buy	393,002 +27,647	+8%	+$1.87M	0.02%	880
2020 Q1	$21.4M	Buy	365,355 +55,884	+18%	+$3.6M	0.01%	971
2019 Q4	$24.8M	Buy	309,471 +5,412	+2%	+$405K	0.01%	1069
2019 Q3	$22.3M	Buy	304,059 +18,186	+6%	+$1.57M	0.01%	1065
2019 Q2	$27M	Buy	285,873 +40,225	+16%	+$3.32M	0.02%	940
2019 Q1	$19.7M	Buy	245,648 +8,673	+4%	+$641K	0.01%	1126
2018 Q4	$12.8M	Buy	236,975 +1,172	+0.5%	+$71.2K	0.01%	1283
2018 Q3	$18.4M	Buy	235,803 +27,508	+13%	+$1.91M	0.01%	1197
2018 Q2	$13.2M	Buy	208,295 +10,042	+5%	+$799K	0.01%	1402
2018 Q1	$18.2M	Buy	198,253 +9,933	+5%	+$856K	0.01%	1069
2017 Q4	$14.2M	Buy	188,320 +19,485	+12%	+$1.37M	0.01%	1240
2017 Q3	$11.8M	Buy	168,835 +13,529	+9%	+$723K	0.01%	1302
2017 Q2	$7.87M	Buy	155,306 +42,848	+38%	+$1.82M	0.01%	1518
2017 Q1	$4.5M	Buy	112,458 +28,306	+34%	+$1.01M	﹤0.01%	1819
2016 Q4	$2.36M	Buy	84,152 +4,736	+6%	+$143K	﹤0.01%	2114
2016 Q3	$2.36M	Buy	79,416 +35,593	+81%	+$884K	﹤0.01%	2058
2016 Q2	$888K	Buy	43,823 +18,320	+72%	+$333K	﹤0.01%	2389
2016 Q1	$461K	Buy	25,503 +510	+2%	+$8.85K	﹤0.01%	2606
2015 Q4	$659K	Buy	24,993 +650	+3%	+$14.6K	﹤0.01%	2529
2015 Q3	$520K	Buy	24,343 +1,709	+8%	+$47.3K	﹤0.01%	2609
2015 Q2	$600K	Buy	+22,634	New	+$646K	﹤0.01%	2616

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Charles Schwab's BPMC Position: Q3 2025 in Review

Charles Schwab sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 561,159 shares — an estimated $71.9M sold.

Charles Schwab first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $71.9M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Charles Schwab reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Charles Schwab sold 561,159 Blueprint Medicines shares in Q3 2025, an estimated $71.9M.
Charles Schwab first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
Charles Schwab's Blueprint Medicines position peaked at $71.9M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.